Open-Label Extension Study of 23 mg Donepezil SR in Participants With Moderate to Severe Alzheimer's Disease
PHASE3CompletedINTERVENTIONAL
Enrollment
915
Participants
Timeline
Start Date
December 14, 2007
Primary Completion Date
April 1, 2010
Study Completion Date
April 1, 2010
Conditions
Alzheimer's Disease
Interventions
DRUG
Donepezil
Donepezil SR 23 mg once daily orally.
Trial Locations (1)
92705
Apex Research Institute, Santa Ana
All Listed Sponsors
collaborator
Eisai Limited
INDUSTRY
lead
Eisai Inc.
INDUSTRY
NCT00566501 - Open-Label Extension Study of 23 mg Donepezil SR in Participants With Moderate to Severe Alzheimer's Disease | Biotech Hunter | Biotech Hunter